ProteomeX LC/MS System

描述（由申请方提供）：要求使用ThermoFinnigan ProteomeX LC/MS。该系统代表了第一个专门为蛋白质组学分析设计的“交钥匙”系统之一。它由一个2D液相色谱前端组成，该前端输入LCQ Deca XP离子阱质谱仪。该系统还包括一个完整的软件包，用于典型的蛋白质组学应用，如蛋白质ID，多维LC/MS和使用ICAT试剂的蛋白质分析。该系统基于非常成功和流行的LCQ Deca XP。由于该仪器允许通过2D LC分离复杂的混合物，因此它是许多蛋白质组学应用的理想选择。质谱仪的动态排除功能允许收集共洗脱离子的数据，从而增加仪器的覆盖信息。在一台仪器中可以进行各种分离和随后的蛋白质ID。此外，该仪器将是理想的蛋白质ID从替代来源，如1D和2D凝胶与提高可靠性，由于能够获得主要序列信息。我们也要求两个附件：一个nanospray附件，它将增加仪器在蛋白质组学工作中的灵敏度，以及一个MALDI源，用于传统MALDI应用中的仪器。该仪器将增强我们目前的SELDI质谱仪，这是初步发现疾病生物标志物的理想选择。ProteomeX系统将使我们能够采取下一步行动，快速识别感兴趣的蛋白质。此外，它将使我们能够扩大我们的能力，研究蛋白质修饰和蛋白质鉴定。该提案的PI目前担任SELDI机构的负责人，并负责纳入ProteomeX系统的添加。核心设施最近获得了一名全职技术人员的资金，作为机构医疗保健差异补助金的一部分。目前正在征聘该职位的人员，到本建议书授标之日将服务一年。我们已经确定了R 01级别支持的五个主要用户。主要用户跨越MSM最大的研究领域，包括：心血管，神经科学，癌症生物学和艾滋病。由于蛋白质组学的普遍性和最近对MSM基因组学的重视，我们认为这次收购将广泛扩展我们的能力，使我们的工作更上一层楼。此外，我们的教师和学生将有机会获得培训和经验，在未来十年最有前途的技术之一。

DESCRIPTION (provided by applicant): A ThermoFinnigan ProteomeX LC/MS is requested. This system represents one of the first "turnkey" systems designed specifically for proteomics analysis. It consists of a 2D Iiquid chromatography front end which feeds into the LCQ Deca XP ion trap mass spectrometer. The system also includes a complete software package for typical proteomics applications such as protein ID, multidimensional LC/MS, and protein profiling using ICAT reagents. The system builds on the very successful and popular LCQ Deca XP. Because the instrument allows separation of complex mixtures by 2D LC it is ideal for many proteomics applications. The mass spec's dynamic exclusion feature allows the collecting of data for co-eluting ions increasing the coverage information of the instrument. In one instrument a variety of separations and subsequent protein IDs can be made. Also, the instrument will be ideal for protein ID from alternative sources such as 1D and 2D gels with improved reliability due to the ability to obtain primary sequence information. We are aIso requesting two attachments: a nanospray attachment, which will increase the sensitivity of the instrument for proteomics work, and a MALDI source to the use of the instrument in traditional MALDI applications. This instrument would augment our current SELDI mass spectrometer, which is ideal for the initial discovery of biomarkers of disease. The ProteomeX system will allow us to take the next step and rapidly identify proteins of interest. In addition, it will allow us to expand our capabilities to investigate protein modifications and protein identification. The PI on this proposal currently serves as the director of the SELDI facility and would have the responsibility to incorporate the addition of the ProteomeX system. The core facility has recently been funded for a full-time technician as a part of an institutional healthcare disparities grant. The person for this position is currently being recruited and will have a year in service by the award date of this proposal. We have identified five primary users with R01 level support. The major users span the largest areas of research at MSM which includes: cardiovascular, neurosciences, cancer biology, and AIDS. Because of the pervasive nature of proteomics and the recent emphasis on genomics at MSM we feel that this acquisition would extensively expand our capabilities to take our work to the next step. In addition, our faculty and students will have the opportunity to gain training and experience in one of the most promising technologies for the next decade.